The August 2026 ELPIS II data readout is the primary catalyst to watch. Positive results could trigger partnership interest and PRV monetization. Monitor for any early safety signals or regulatory updates ahead of the readout.
Price Chart
Executive Summary
Longeveron issued a CEO letter detailing a strategic repositioning toward a capital-light, partnership-focused model, with key near-term catalyst being top-line data from the Phase 2b HLHS trial (ELPIS II) expected in August 2026. The company completed a March 2026 private placement for up to $30M ($15M upfront) from institutional investors. No financial results were reported.
Key Financial Metrics
Key Facts
- CEO Stephen Willard outlines strategic shift to partnership model and capital-light operations
- Phase 2b ELPIS II HLHS top-line data expected August 2026
- March 2026 private placement raised up to $30M ($15M upfront, $15M milestone-based)
- Laromestrocel has six FDA designations including RMAT for Alzheimer's and Rare Pediatric Disease for HLHS
- Eligible for Priority Review Voucher (PRV) upon HLHS approval, valued at $150M-$200M
Financial Impact
No immediate financial impact; potential catalyst in August 2026 could significantly affect valuation if trial results are positive. Private placement provides up to $30M in gross proceeds.
Risk Factors
- Clinical trial failure in ELPIS II could severely depress stock
- Dilution from milestone-based tranches of private placement
- Going concern risk if financing not secured or trial results negative
- Reliance on strategic partnerships for Alzheimer's and frailty programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298860 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | 8-K | $6.86 $2.49 | ▼ −63.70% | ▼ −64.52% | $2.57 (−62.61%) |
Jul 13, 2026 11w ago | 3 | $0.6223 $0.6022 | ▼ −3.23% | ▼ −1.93% | $2.57 (+312.18%) |
Jun 5, 2026 16w ago | 8-K | $0.7540 $0.7900 | ▲ +4.77% | ▲ +2.66% | $2.57 (+240.19%) |
May 20, 2026 19w ago | Press Release | $0.7210 $0.8150 | ▲ +13.04% | ▲ +11.44% | $2.57 (+255.76%) |
May 13, 2026 20w ago | 8-K | $0.7030 $0.7210 | ▲ +2.56% | ▲ +3.28% | $2.57 (+264.86%) |
May 8, 2026 20w ago | 8-K | $0.8380 $0.6760 | ▲ +19.33% | ▲ +19.25% | $2.57 (−206.09%) |
Apr 20, 2026 23w ago | EFFECT | $1.04 $0.9000 | ▲ +13.46% | ▲ +14.37% | $2.57 (−146.63%) |
Apr 10, 2026 24w ago | 8-K | $1.12 $1.04 | ▼ −7.14% | ▼ −10.44% | $2.57 (+129.02%) |
Apr 10, 2026 24w ago | S-1 | $1.12 $1.04 | ▲ +7.14% | ▲ +10.44% | $2.57 (−129.02%) |
Mar 17, 2026 28w ago | Press Release | $0.9760 $0.9730 | ▲ +0.31% | ▼ −0.41% | $2.57 (−162.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access